Related Experiment Video
Updated: Apr 19, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Comorbidity increases the risk of hospitalizations in multiple sclerosis
Ruth Ann Marrie1, Lawrence Elliott2, James Marriott2
1From the Departments of Internal Medicine (R.A.M., J.M., M.C., A.T., N.Y.) and Community Health Sciences (R.A.M., L.E.), University of Manitoba, Winnipeg, Canada. rmarrie@hsc.mb.ca.
Objective:
We aimed to evaluate the association between comorbidity and rates of hospitalization in the multiple sclerosis (MS) population as compared to a matched cohort from the general population.
Methods:
Using population-based administrative data from the Canadian province of Manitoba, we identified 4,875 persons with MS and a matched general population cohort of 24,533 persons. We identified all acute care hospitalizations in the period 2007-2011. Using general linear models, we evaluated the association between comorbidity status and hospitalization rates (all-cause, non-MS-related, MS-related) in the 2 populations, adjusting for age, sex, and socioeconomic status.
Results:
Comorbidity was common in both cohorts. Over the 5-year study period, the MS population had a 1.5-fold higher hospitalization rate (adjusted rate ratio [aRR] 1.56; 95% confidence interval [CI] 1.44-1.68) than the matched population. Any comorbidity was associated with a 2-fold increased risk of non-MS-related hospitalization rates (aRR 2.21; 95% CI 1.73-2.82) in the MS population, but a nearly 4-fold increase in hospitalization rates in the matched population (aRR 3.85; 95% CI 3.40-4.35). Comorbidity was not associated with rates of hospitalization for MS-related reasons, regardless of how comorbidity status was defined.
Conclusions:
In the MS population, comorbidity is associated with an increased risk of all-cause hospitalizations, suggesting that the prevention and management of comorbidity may reduce hospitalizations.
Insights
Comorbidity significantly increases hospitalization rates in multiple sclerosis (MS) patients. Managing these conditions may reduce hospital admissions for individuals with MS.
Area of Science:
- Neurology
- Public Health
- Epidemiology
Background:
- Multiple sclerosis (MS) is a chronic neurological disease.
- Comorbidity is prevalent in the MS population.
- Understanding hospitalization drivers in MS is crucial for healthcare management.
Purpose of the Study:
- To compare hospitalization rates between individuals with MS and a matched general population cohort.
- To evaluate the association between comorbidity and hospitalization rates in the MS population.
Main Methods:
- Utilized population-based administrative data from Manitoba, Canada (2007-2011).
- Included 4,875 persons with MS and 24,533 matched controls.
- Employed general linear models to analyze hospitalization rates (all-cause, non-MS-related, MS-related) adjusted for covariates.
Main Results:
- The MS population experienced a 1.5-fold higher overall hospitalization rate compared to controls.
- Comorbidity was linked to a 2-fold increased risk of non-MS-related hospitalizations in the MS cohort.
- Comorbidity did not significantly affect MS-related hospitalization rates.
Conclusions:
- Comorbidity is a significant risk factor for all-cause hospitalizations in individuals with MS.
- Effective prevention and management of comorbidities may lead to reduced hospitalizations in the MS population.
Related Concept Videos
Multiple Sclerosis l: Introduction
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Factors Affecting Illness
For instance, risk factors are connected to illness,...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations
Heart Failure III: Clinical Manifestations

